Nadia Waheed, MD
Uveitis and Ocular Inflammatory Disease · Boston, MANPI 1245214915
Payments from drug & device makers
Across 163 payments — averaging $6757.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Regeneron$499K
- Topcon Corporation$212K
- Topcon Healthcare, Inc.$115K
- Boehringer Ingelheim International GmbH$71K
- Genentech, Inc.$53K
- F. Hoffmann-la Roche AG$52K
- plus $101K from 12 others
Across 4 payments — averaging $3032.46 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Topcon Corporation$10K
- F. Hoffmann-la Roche AG$2K
- Regeneron$194
What the payments were for
- Consulting fees$220,83664%
- Speaking & faculty fees$76,49822%
- Travel & lodging$45,09513%
- Food & beverage$3,7651%
- Education$150%
- Gifts$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Regeneron | 6 | $498,581 |
| Topcon Corporation | 16 | $211,785 |
| Topcon Healthcare, Inc. | 32 | $114,656 |
| Boehringer Ingelheim International GmbH | 12 | $71,172 |
| Genentech, Inc. | 19 | $52,641 |
| F. Hoffmann-la Roche AG | 23 | $51,537 |
| Novartis | 24 | $41,581 |
| Grifols, S.A. | 2 | $27,327 |
| Nidek CO., LTD. | 5 | $13,000 |
| Alcon Research LLC | 5 | $11,044 |
| Nidek Incorporated | 1 | $4,938 |
| Alcon | 5 | $1,407 |
| Samsung Bioepis Co., Ltd. | 1 | $1,000 |
| Carl Zeiss Meditec, Inc. | 6 | $377 |
| Boehringer Ingelheim | 1 | $315 |
| Genentech USA, Inc. | 2 | $83 |
| Regeneron Healthcare Solutions, Inc. | 2 | $45 |
| Alimera Sciences, Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered Product$47,023
- BEOVU$37,698
- Lucentis$15,097
- Mirante$8,500
- OCT TRITON$6,863
- OCT MAESTRO$4,363
- OCT-MAESTRO2$2,500
- CIRRUS HD-OCT$112
- PLEX Elite 9000$112
- Clarus 700$112
How this compares
Too few uveitis and ocular inflammatory disease providers in Massachusettsto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other uveitis and ocular inflammatory disease in Boston
- Caroline BaumalBoston$2M
- Elias ReichelBoston$950K
- Lana RifkinBoston$106K
- Jay DukerBoston$22K
- Andrew TyeBoston$918
- Sarkis SoukiasianBurlington$196
- Arnold KrollMilford$118
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.